{"name":"Green Cross Corporation","slug":"green-cross-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"cardiovascular","drugs":[{"name":"GC3110A(Trivalent)","genericName":"GC3110A(Trivalent)","slug":"gc3110a-trivalent","indication":"Other","status":"phase_3"},{"name":"MG1109","genericName":"MG1109","slug":"mg1109","indication":"Other","status":"phase_3"},{"name":"GC FLU inj.","genericName":"GC FLU inj.","slug":"gc-flu-inj","indication":"Seasonal influenza prevention in adults and children","status":"phase_3"},{"name":"GC Flu(Trivalent)","genericName":"GC Flu(Trivalent)","slug":"gc-flu-trivalent","indication":"Seasonal influenza prevention in adults and children","status":"phase_3"},{"name":"GC3110A(Quadrivalent)","genericName":"GC3110A(Quadrivalent)","slug":"gc3110a-quadrivalent","indication":"Indication not publicly specified for GC3110A(Quadrivalent) in Phase 3","status":"phase_3"},{"name":"GC3111 vaccine","genericName":"GC3111 vaccine","slug":"gc3111-vaccine","indication":"Other","status":"phase_2"},{"name":"GCFLU Pre-filled Syringe inj.","genericName":"GCFLU Pre-filled Syringe inj.","slug":"gcflu-pre-filled-syringe-inj","indication":"Seasonal influenza prevention in adults and children","status":"phase_3"},{"name":"GCFLU Quadrivalent","genericName":"GCFLU Quadrivalent","slug":"gcflu-quadrivalent","indication":"Other","status":"phase_2"},{"name":"GCFLU Quadrivalent Inj. vaccine","genericName":"GCFLU Quadrivalent Inj. vaccine","slug":"gcflu-quadrivalent-inj-vaccine","indication":"Seasonal influenza prevention in adults and children","status":"phase_3"},{"name":"Hunterase","genericName":"Hunterase","slug":"hunterase","indication":"Mucopolysaccharidosis type II","status":"phase_3"},{"name":"I.V HBIG","genericName":"I.V HBIG","slug":"i-v-hbig","indication":"Other","status":"phase_2"},{"name":"Immunoglobulin G","genericName":"Immunoglobulin G","slug":"immunoglobulin-g","indication":"Other","status":"marketed"},{"name":"Shinbaro Capsule","genericName":"Shinbaro Capsule","slug":"shinbaro-capsule","indication":"Other","status":"marketed"},{"name":"Suduvax","genericName":"Suduvax","slug":"suduvax","indication":"Other","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"neuroscience","drugs":[{"name":"GC5131","genericName":"GC5131","slug":"gc5131","indication":"Type 2 diabetes","status":"phase_2"},{"name":"GreenGene","genericName":"GreenGene","slug":"greengene","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Step 1","genericName":"Step 1","slug":"step-1","indication":"Diabetes mellitus, type 1","status":"marketed"},{"name":"GC3102C","genericName":"GC3102C","slug":"gc3102c","indication":"Type 2 diabetes","status":"phase_3"},{"name":"GC3110A","genericName":"GC3110A","slug":"gc3110a","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"GC1107","genericName":"GC1107","slug":"gc1107","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"GC3110A vaccine","genericName":"GC3110A vaccine","slug":"gc3110a-vaccine","indication":"Advanced or metastatic cancer (specific indication under investigation in phase 3)","status":"phase_3"},{"name":"GC3110B vaccine","genericName":"GC3110B vaccine","slug":"gc3110b-vaccine","indication":"Advanced or metastatic cancer (specific indication under investigation in phase 3)","status":"phase_3"},{"name":"Intradermal BCG SSI inj.","genericName":"Intradermal BCG SSI inj.","slug":"intradermal-bcg-ssi-inj","indication":"Non-muscle invasive bladder cancer (established use)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"GC3107","genericName":"GC3107","slug":"gc3107","indication":"Chronic hepatitis B","status":"phase_3"},{"name":"Hantavax injection","genericName":"Hantavax injection","slug":"hantavax-injection","indication":"Prevention of hemorrhagic fever with renal syndrome (HFRS) caused by hantavirus infection","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"GreenGene™ F","genericName":"GreenGene™ F","slug":"greengene-f","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Human immunoglobulin intravenous","genericName":"Human immunoglobulin intravenous","slug":"human-immunoglobulin-intravenous","indication":"Primary immunodeficiency disorders","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Step 2","genericName":"Step 2","slug":"step-2","indication":"Treatment of opioid use disorder","status":"marketed"}]}],"pipeline":[{"name":"GC1107","genericName":"GC1107","slug":"gc1107","phase":"phase_3","mechanism":"GC1107 is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from inhibiting T cell activation.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"GC3107","genericName":"GC3107","slug":"gc3107","phase":"phase_3","mechanism":"GC3107 is a recombinant human albumin-fused interferon alpha (IFN-α) fusion protein that enhances antiviral and immunomodulatory activity.","indications":["Chronic hepatitis B","Chronic hepatitis C"],"catalyst":""},{"name":"GC3110A(Trivalent)","genericName":"GC3110A(Trivalent)","slug":"gc3110a-trivalent","phase":"phase_3","mechanism":"GC3110A is a trivalent vaccine designed to stimulate immune responses against multiple targets for therapeutic benefit.","indications":[],"catalyst":""},{"name":"GC5131","genericName":"GC5131","slug":"gc5131","phase":"phase_2","mechanism":"GC5131 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"GreenGene","genericName":"GreenGene","slug":"greengene","phase":"phase_3","mechanism":"GreenGene is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"MG1109","genericName":"MG1109","slug":"mg1109","phase":"phase_3","mechanism":"MG1109 is a therapeutic agent in development by Green Cross Corporation currently in phase 3 clinical trials.","indications":[],"catalyst":""},{"name":"Step 1","genericName":"Step 1","slug":"step-1","phase":"marketed","mechanism":"Step 1 is a recombinant human insulin used to lower blood glucose levels in people with diabetes.","indications":["Diabetes mellitus, type 1","Diabetes mellitus, type 2"],"catalyst":""},{"name":"GC FLU inj.","genericName":"GC FLU inj.","slug":"gc-flu-inj","phase":"phase_3","mechanism":"GC FLU is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"GC Flu(Trivalent)","genericName":"GC Flu(Trivalent)","slug":"gc-flu-trivalent","phase":"phase_3","mechanism":"GC Flu(Trivalent) is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against three strains of influenza virus.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"GC3102C","genericName":"GC3102C","slug":"gc3102c","phase":"phase_3","mechanism":"GC3102C is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes","Chronic kidney disease"],"catalyst":""},{"name":"GC3110A","genericName":"GC3110A","slug":"gc3110a","phase":"phase_3","mechanism":"GC3110A is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"GC3110A vaccine","genericName":"GC3110A vaccine","slug":"gc3110a-vaccine","phase":"phase_3","mechanism":"GC3110A is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.","indications":["Advanced or metastatic cancer (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"GC3110A(Quadrivalent)","genericName":"GC3110A(Quadrivalent)","slug":"gc3110a-quadrivalent","phase":"phase_3","mechanism":"GC3110A is a quadrivalent vaccine designed to stimulate immune responses against multiple disease targets.","indications":["Indication not publicly specified for GC3110A(Quadrivalent) in Phase 3"],"catalyst":""},{"name":"GC3110B vaccine","genericName":"GC3110B vaccine","slug":"gc3110b-vaccine","phase":"phase_3","mechanism":"GC3110B is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.","indications":["Advanced or metastatic cancer (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"GC3111 vaccine","genericName":"GC3111 vaccine","slug":"gc3111-vaccine","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"GCFLU Pre-filled Syringe inj.","genericName":"GCFLU Pre-filled Syringe inj.","slug":"gcflu-pre-filled-syringe-inj","phase":"phase_3","mechanism":"GCFLU is a pre-filled syringe formulation of an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"GCFLU Quadrivalent","genericName":"GCFLU Quadrivalent","slug":"gcflu-quadrivalent","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"GCFLU Quadrivalent Inj. vaccine","genericName":"GCFLU Quadrivalent Inj. vaccine","slug":"gcflu-quadrivalent-inj-vaccine","phase":"phase_3","mechanism":"GCFLU Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"GreenGene™ F","genericName":"GreenGene™ F","slug":"greengene-f","phase":"phase_3","mechanism":"GreenGene F is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes","Heart failure"],"catalyst":""},{"name":"Hantavax injection","genericName":"Hantavax injection","slug":"hantavax-injection","phase":"phase_3","mechanism":"Hantavax is an inactivated vaccine that stimulates the immune system to produce antibodies against hantavirus, preventing infection with hantaviruses that cause hemorrhagic fever with renal syndrome (HFRS).","indications":["Prevention of hemorrhagic fever with renal syndrome (HFRS) caused by hantavirus infection"],"catalyst":""},{"name":"Human immunoglobulin intravenous","genericName":"Human immunoglobulin intravenous","slug":"human-immunoglobulin-intravenous","phase":"phase_3","mechanism":"Human immunoglobulin intravenous (IVIG) provides passive immunity by delivering pooled antibodies from multiple human donors to neutralize pathogens and modulate immune responses.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency (e.g., in hematologic malignancies or post-transplant)","Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome)","Recurrent infections in immunocompromised patients"],"catalyst":""},{"name":"Hunterase","genericName":"Hunterase","slug":"hunterase","phase":"phase_3","mechanism":"Biologic","indications":["Mucopolysaccharidosis type II"],"catalyst":""},{"name":"I.V HBIG","genericName":"I.V HBIG","slug":"i-v-hbig","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Immunoglobulin G","genericName":"Immunoglobulin G","slug":"immunoglobulin-g","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Intradermal BCG SSI inj.","genericName":"Intradermal BCG SSI inj.","slug":"intradermal-bcg-ssi-inj","phase":"phase_3","mechanism":"Intradermal BCG (Bacillus Calmette-Guérin) stimulates the immune system by activating innate and adaptive immunity to enhance anti-tumor or anti-infectious responses.","indications":["Non-muscle invasive bladder cancer (established use)","Melanoma or other solid tumors (investigational)"],"catalyst":""},{"name":"Shinbaro Capsule","genericName":"Shinbaro Capsule","slug":"shinbaro-capsule","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Step 2","genericName":"Step 2","slug":"step-2","phase":"marketed","mechanism":"Step 2 is a medication used to treat opioid use disorder.","indications":["Treatment of opioid use disorder"],"catalyst":""},{"name":"Suduvax","genericName":"Suduvax","slug":"suduvax","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNbkVVSzdNWUlhbkpEdERDbzhIQUk4ZlN0MkpMMjFXQk04b19FY1lkdnpiV0VKb0g3bldOT1dMUDlEZ1RLeXBSc2dCc19xMFBNSFVINUlYQTl0OVpTZGRCZzdub2RvM0lOQ212cFBGZm4tSHRiQW12VEpuOXg2SHg3djRmYUxJcjB0dGpVcDR4MEJRdUs4bFdQVEJqTkxoVHpMQmF0TEhwaFhLU2pDVEpMVi01SW56R2FYekt4d0hvWjRlZw?oc=5","date":"2026-04-06","type":"pipeline","source":"Contract Pharma","summary":"GC Biopharma Validates Proprietary Technology to Mitigate Thromboembolic Risks - Contract Pharma","headline":"GC Biopharma Validates Proprietary Technology to Mitigate Thromboembolic Risks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5HMkJVQ3dsczhPQXBPWHlEMU94WU9vdUJCV1pxNEdudzVEZkJmRDNaUTNqeV84bFRTVnJXMk4wMGFRVnQtWkF5cGwxM04zdm5FUnRwUGIxVzZqbEtvWHZILVlQa0lVOVZXNzJmeVlfZGNkRjY1?oc=5","date":"2026-02-12","type":"pipeline","source":"Businesskorea","summary":"Eight Domestic Pharma Companies Exceed 1 Trillion Won Sales Last Year - Businesskorea","headline":"Eight Domestic Pharma Companies Exceed 1 Trillion Won Sales Last Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOX1VBRnZyYVJiSGd1WHlkS2tMZnJLQllneDlnZldtakN1Qk9ZR0g0aU1NS1ZlY0FjYmFBa2lPX0xGaE9BcEptaGEwY1A0UkYwamNMSkRmSDl0aXNkb3dwd0wxbDBaOEUya0lycjg1VFZROFhvd1pUbDAyaVdVU2dVTnNsamUzT3AxZXlEUUZhVzR1VFk5VzV0VE50VW5fWmFvMXFjcnNHbURsTmZDbkFURmVHeGF1OHczNVF5UHNtM3lQZUxvdXVJSU0zdkFGNU1icmhJMWxZNGNRM0ptemc?oc=5","date":"2024-11-26","type":"trial","source":"BioSpace","summary":"GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment - BioSpace","headline":"GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNV256TzkyUlVNQ0xINExwUDE5NW9KVVFrd0VrS2pjMXMyWjl4aHJaN3NXeU1XclNQem5HQkZ3a2VYRjJCXzczWjZaTGNQUzE5VDZRZTZTcWpFS3otdWltc2poT0xVR19xTERiaUpjQjc4eGZ2OE9SU3lHUHp5d0lQRGFSeUVJOTNFeGFuQm9WMUVGZTRzRzJlT1lkWXI2cm45OElEX2FWU1B4bzdoN1IwcVY0bXBzMTN5UnQxTUliZGpmVDQ?oc=5","date":"2024-07-18","type":"deal","source":"Yicai Global","summary":"China Resources Boya Slumps on USD251 Million Deal to Pay Nearly 200% Premium for Plasma Firm - Yicai Global","headline":"China Resources Boya Slumps on USD251 Million Deal to Pay Nearly 200% Premium for Plasma Firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNSnNrcGloWjA2NXhDNWVSLS1SQ1pWQjBFMDh5cXdfdU04T3VoX1V5SlQzaUZpOU52cy13MmhqMlhVR19TZUdtY3dxWHM1MWphSUZNWUpQZkZLWUhsZlgyWXJyLXJXTEtYYWRIWTU1bWVmckEzNTgxUlVsYWMzT3dLb0pDc0lxb0tnd3RVbVI3azY?oc=5","date":"2023-10-11","type":"pipeline","source":"pharmaphorum","summary":"South Korea: Emerging global leader in life sciences - pharmaphorum","headline":"South Korea: Emerging global leader in life sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNbm9WTFNXZ2F2dVRPQlotdFdLTjY2b1FhSUlJZ3MtRW1lS0g2T3R1bHRKdFY5TjR1ZEpLbFBiTFZxQW9XdG5pTHdDMHV4U3I5SjR4S0x2Ni05WnA1aDA4Z2R5MG94WXV6MnBWaFgtQ2RuWW9BcU5CUHdOUEFsLU85UmhpNy1Pcjd4QzE0UkNjblF1dnlSMFRSdUJpX3otcTlk?oc=5","date":"2022-03-29","type":"pipeline","source":"businesswire.com","summary":"GC Pharma Changes Its Name to “GC Biopharma” - businesswire.com","headline":"GC Pharma Changes Its Name to “GC Biopharma”","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNZ0xadUl2MmhIUHJEVk01S1BGelVIQTB6UDZSbTBNQ2xDYWNKRUduWUY5QkdVczdBa3h2ajNONHNGaGpqM1oxTlg5akRYc0psNzFEQl9fbEZONktzaTUzSHFPV01JUUlmMmFKX0t0UHNqV0NDRXV1VkVseENjdFZubmtOR0JwYW50Zy1rU1hlUGMxZ01hSkNJVlRnZmdodWJZck9qLThQWVAyS0ZXTnhr?oc=5","date":"2022-03-01","type":"regulatory","source":"Fierce Pharma","summary":"FDA pushes back GC Pharma's blood derivative approval due to inspection delay - Fierce Pharma","headline":"FDA pushes back GC Pharma's blood derivative approval due to inspection delay","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxObmpKc2VEQnZmR0NsaVBPTExLNEJQRkZFcU93RDNvYmRPeGVzelh1dU5uUEhtSDJfVTFQS3duRGViZENmYTI5d2pWczQ5RW95dzRFNjRwYlJJQVVjamxpY3NNZHp6dHEwSlI5VFB5VTBjR3B4Z3ZwOTFmSmFWX19Sa0MweHR3LXYwejk3NkJTTGVHaE9XeEo1V1JzcllPTVFTT0dXR1B5NkFOaXhUd3lwN0luQ2hmQnBBR1o0dzB3RkowYjJzX3VkaVduVzFLaENxdjRPZy1FUTg?oc=5","date":"2021-08-12","type":"regulatory","source":"businesswire.com","summary":"GC Pharma Announces GreenGene F Approval in China for the Treatment of Haemophilia A - businesswire.com","headline":"GC Pharma Announces GreenGene F Approval in China for the Treatment of Haemophilia A","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9oSGZJaUdNTms4d0Z2TmFMejFNODRBV0pubzV2MUVfREk5TXpNaFd4Q0ZNYjFxdUF1bVIwaktlYjJCR0lVTmNMSDNvbEdoQjIyRU5tOWdVOFkzdWc4Q0JJ?oc=5","date":"2021-07-18","type":"pipeline","source":"KED Global","summary":"Green Cross' two Kosdaq-listed cell therapy arms to merge - KED Global","headline":"Green Cross' two Kosdaq-listed cell therapy arms to merge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNQmNYLWZKUDNwNnNDb1FaUi1sSGxYSlVuRTJlV0tBSUh5X1N0UWVuWDdyRWxrSnNtQVRWT3pQZWUzcFFmRFB0aS1tUGxSazBxdGI2MFZhMWtUUm1FTHgtR29UOFZfMktSdG5XM3g0YzZ5NjhjbndTUnlyVlpqbzB6OWpXYmV5blBnc0RpdXBCVkN0b1FiVmlZdUYwbjlETGlOX3JzcFhyS1p4dkp4ZG9iVWQtWjB2dTdURWhkRENjeVJkbVhYeGVPeGJmV3NpWXB4U2V5SnF0NEhMcXhYY1VoNnVNbDVYMVgtRG16TG5tNTgxa1ZRLTFzNW4wN01JTDNyNk9HdHRMWDZYQW1qbktLOUtpY3JPRVRB?oc=5","date":"2018-02-13","type":"pipeline","source":"prnewswire.com","summary":"GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant - prnewswire.com","headline":"GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigationa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQWjl3ckhmZEVEb24xOHR0cVBVYXZGTWdmM1JDYUpzWWJjSi11Z0YxNVZhdjJocWFWSG5KUTdtaWtJaUJWNUc0OFMzM1FoQzJUYVVLWDhJVzd2eFdSYThGWjNoc2tDdEYzREdlRzV0NTc3aDNvV0NPZUtPMjctUDh5TWZEN29JNi1wcmx5dURUbmFZZlBJWmgwcUVDYnRXVW96VW5UQw?oc=5","date":"2018-01-02","type":"pipeline","source":"prnewswire.com","summary":"Green Cross Introduces Its New Master Brand \"GC\" - prnewswire.com","headline":"Green Cross Introduces Its New Master Brand \"GC\"","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPdlhWZnNuUUhhVFZQSTFTZFFsenF1VXF2NV9UZlFnRG5zSi05UWlNOHNxczk4a0V1YnVjdVRMMjFCZ2VVUUlpbl8xNjM3RlBsczNKUHZER1pIRHlfV3BvNV9qWHUydGdVal9RSEpJRXFFRGpHWVAwTXFGVHdUODJEVWFCTDllTVo5UVRNLXZjY0RpZGJDb2hnbUFrM2dDWjhyNTVVRQ?oc=5","date":"2015-08-07","type":"pipeline","source":"Pharmaceutical Technology","summary":"Green Cross Biotherapeutics Biomanufacturing Facility, Montreal, Canada - Pharmaceutical Technology","headline":"Green Cross Biotherapeutics Biomanufacturing Facility, Montreal, Canada","sentiment":"neutral"}],"patents":[],"drugCount":28,"phaseCounts":{"phase_3":19,"phase_2":5,"marketed":4},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}